A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Pfizer
Study ID
NCT07508241
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Accepted

Interventions

  • PF-08653944 — DRUG
    Subcutaneous Injection
  • Acetaminophen — DRUG
    Oral suspension

Study Details

This study looks at how a study medicine called PF-08653944 affects how quickly the stomach empties food after eating. It is being done in adults who are overweight or have obesity. Participants will receive the study medicine for a short period, and doctors will measure how the medicine moves through the stomach and monitor safety. The goal is to better understand how this medicine works in the body and to check for any side effects. The information from this study may help researchers plan future studies of this medicine.

Key Dates

Start date
Mar 31, 2026
Status verified
Apr 2026
Primary completion
Jan 27, 2027
Completion
Jan 27, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Period 1
    Participants will receive a single oral dose of acetaminophen.
  • Experimental: Period 2
    Participants will receive SC dose of PF-08653944 and single oral dose of acetaminophen.
  • Experimental: Period 3
    Participants will receive SC dose of PF-0865394.
  • Experimental: Period 4
    Participants will receive SC dose of PF-0865394.
  • Experimental: Period 5
    Participants will receive SC dose of PF-08653944 and single oral dose of acetaminophen.
  • Experimental: Period 6
    Participants will receive single SC dose of PF-08653944 and single oral dose of acetaminophen.

Primary Outcome Measure

Acetaminophen Pharmacokinetic (PK) Parameters: Maximum observed plasma concentration (Cmax) [ Time Frame: Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Pfizer Clinical Research Unit - New HavenNew HavenConnecticut06511-

Find similar trials in New Haven, CT

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Pfizer Clinical Research Unit - New Haven· New Haven, CT

Related Studies